XASXNTI
Market cap34mUSD
Jan 09, Last price
0.05AUD
1D
1.89%
1Q
3.85%
Jan 2017
-83.97%
IPO
-79.43%
Name
Neurotech International Ltd
Chart & Performance
P/E
—
P/S
28,667.59
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
50.45%
Rev. gr., 5y
-60.12%
Revenues
2k
-67.06%
Net income
-5m
L-34.94%
CFO
-5m
L-27.25%
Earnings
Feb 27, 2025
Profile
Neurotech International Limited, together with its subsidiaries, engages in the research, design, development, and manufacture of medical devices and solutions in Australia. The company is focused on development and commercializing Mente platform, a platform technology to monitor and play role in home-based therapies. Its product includes Mente Autism for the diagnosis and treatment of autism. It also engages in executing of medical research projects; and developing of technological devices. The company was incorporated in 2016 and is based in Nedlands, Australia.
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | 2016‑06 | |
| Income | |||||||||
Revenues | 2 -67.06% | 6 -84.43% | 38 -81.44% | ||||||
Cost of revenue | 7,634 | 7,414 | 3,874 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | (7,632) | (7,408) | (3,836) | ||||||
NOPBT Margin | |||||||||
Operating Taxes | (3,175) | (1,189) | (569) | ||||||
Tax Rate | |||||||||
NOPAT | (4,456) | (6,220) | (3,267) | ||||||
Net income | (5,069) -34.94% | (7,792) 131.75% | (3,362) -54.75% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 11,195 | 9,447 | 26 | ||||||
BB yield | -17.54% | -29.57% | -0.05% | ||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | (11,625) | (5,026) | (1,895) | ||||||
| Cash flow | |||||||||
Cash from operating activities | (4,595) | (6,317) | (2,955) | ||||||
CAPEX | 4,595 | (3) | |||||||
Cash from investing activities | (3) | ||||||||
Cash from financing activities | 11,195 | 9,447 | 26 | ||||||
FCF | (4,729) | (6,218) | (3,269) | ||||||
| Balance | |||||||||
Cash | 11,625 | 5,026 | 1,895 | ||||||
Long term investments | |||||||||
Excess cash | 11,625 | 5,025 | 1,894 | ||||||
Stockholders' equity | 11,899 | 3,962 | 1,430 | ||||||
Invested Capital | 273 | ||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 911,962 | 798,772 | 697,273 | ||||||
Price | 0.07 75.00% | 0.04 -42.86% | 0.07 32.08% | ||||||
Market cap | 63,837 99.80% | 31,951 -34.54% | 48,809 86.95% | ||||||
EV | 52,212 | 26,925 | 46,914 | ||||||
EBITDA | (7,631) | (7,407) | (3,836) | ||||||
EV/EBITDA | |||||||||
Interest | 1 | ||||||||
Interest/NOPBT | |||||||||